Evidence map›Paper›PMID 40846330›Full record

Observational studyBMJ open2025

Potential drug-drug interactions among hospitalised cardiac patients in Nepal: a prospective observational study.

Binod Kumar Sah, Arun Kumar Karna, Sangam Subedi, Ranjit Kumar Sah, Sunil Shrestha, Nim Bahadur Dangi

Abstract readObservational Study
In one paragraph

Observational study in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Binod Kumar SahPharmaceutical Sciences Program, School of Health and Allied Sciences, Pokhara University, Pokhara, Gandaki, Nepal binodksah2073@gmail.com sunilcresta@gmail.com.ORCID http://orcid.org/0000-0001-9293-7551
Arun Kumar KarnaDepartment of Medicine, Narayani Hospital, Birgunj, 44300 Parsa, Province Madhesh, Nepal.
Sangam SubediPharmaceutical Sciences Program, School of Health and Allied Sciences, Pokhara University, Pokhara, Gandaki, Nepal.
Ranjit Kumar SahDepartment of Pharmacy, Narayani Hospital, Birgunj, 44300 Parsa, Province Madhesh, Nepal.
Sunil ShresthaDepartment of Research and Academics, Kathmandu Cancer Center, Tathali, Nala Road, Province Bagmati, Nepal binodksah2073@gmail.com sunilcresta@gmail.com.
Nim Bahadur DangiPharmaceutical Sciences Program, School of Health and Allied Sciences, Pokhara University, Pokhara, Gandaki, Nepal.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDrug-drug interactions (DDIs) are a significant concern for patients on complex therapeutic regimens, especially involving cardiovascular medications, which are frequently implicated in these interactions.

objectivesThis study used a standardised interaction database to determine the frequency, severity and risk factors associated with potential DDIs (pDDIs) among cardiovascular disease (CVD) in-patients.

methodsThe prospective cross-sectional study was conducted at a tertiary care hospital in Nepal from April 2024 to October 2024. A total of 106 eligible CVD in-patients were evaluated for pDDIs using the Lexicomp DDI checker database, and the interactions were categorised based on severity and risk rating. Binary logistic regression identified factors associated with pDDIs.

resultsThe study identified 621 pDDIs using the Lexicomp database, with median values of 8 pDDIs per patient. Patients with at least one pDDI comprised 64.2% of the sample. Most pDDIs were of moderate severity (77.3%) with risk ratings of C (65.7%). The most common cardiovascular medications involved in the detected DDI pairs were diuretics (31.2%), antiplatelets and anticoagulants (23.8%) and calcium channel blockers (12.2%). Multivariate binary logistic regression revealed that patients who stayed longer (adjusted OR (AOR) 9.08, 95% CI 1.027 to 80.216, p=0.047), those receiving more medications (AOR 18.85, 95% CI 2.975 to 119.370, p=0.002) and those who were admitted to the intensive cardiac care unit (AOR 16.31, 95% CI 2.728 to 97.461, p=0.002) were significantly more likely to experience pDDIs.

conclusionsThis study found a higher prevalence of pDDIs. It is advisable to incorporate medication reviews into routine cardiac care and use a drug interaction checker to identify pDDIs.

Indexed as

Cardiovascular AgentsCardiovascular DiseasesAdultAgedCalcium Channel BlockersCross-Sectional StudiesDrug InteractionsFemaleHospitalizationHumansLogistic ModelsMaleMiddle AgedNepalProspective StudiesRisk FactorsCalcium Channel BlockersCardiovascular AgentsAdverse eventsCLINICAL PHARMACOLOGYDrug TherapyPolypharmacy

Identifiers

PMID40846330
PMCPMC12374666

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.